Scientific work

Prof. Dr. Meral Beksaç

911 publications. The source of the information is stated next to each publication.

Back to profile

  1. Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source: ORCID

  2. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, 2024

    DOI 10.3324/haematol.2023.284325 PMID 38299578 24 citations (Europe PMC) Open-access full textSource: ORCID

  3. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

    Haematologica, 2024

    DOI 10.3324/haematol.2023.284520 PMID 38546696 2 citations (Europe PMC) Open-access full textSource: ORCID

  4. Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

    Clinical Lymphoma Myeloma and Leukemia, 2024

    DOI 10.1200/jco.2024.42.16_suppl.7500 7 citations (OpenAlex) Open-access full textSource: ORCID

  5. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

    Clinical Lymphoma, Myeloma and Leukemia, 2024

    DOI 10.1016/j.clml.2023.10.009 PMID 38072743 7 citations (Europe PMC) Open-access full textSource: ORCID

  6. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

    Leukemia, 2024

    DOI 10.1038/s41375-023-02105-6 PMID 38062124 17 citations (Europe PMC) Open-access full textSource: ORCID

  7. Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

    Blood, 2024

    DOI 10.1182/blood-2024-200165 2 citations (OpenAlex) Open-access full textSource: ORCID

  8. Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma Myeloma and Leukemia, 2024

    DOI 10.1016/s2152-2650(24)01903-7 1 citation (OpenAlex) Source: ORCID

  9. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.17_suppl.lba105 13 citations (OpenAlex) Open-access full textSource: ORCID

  10. Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.7506 24 citations (OpenAlex) Open-access full textSource: ORCID

  11. Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation, 2024

    DOI 10.1038/s41409-024-02460-7 PMID 39533015 3 citations (Europe PMC) Source: ORCID

  12. Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source: ORCID

  13. The Many Faces of Multiple Myeloma,Multipl Myelomun Farklı Yüzleri

    Turkish Journal of Hematology, 2024

    DOI 10.4274/tjh.galenos.2023.2023.0183 PMID 37540065 Open-access full textSource: ORCID

  14. Transcriptome Analysis of Beta-Catenin-Related Genes in CD34+ Haematopoietic Stem and Progenitor Cells from Patients with AML

    Mediterranean Journal of Hematology and Infectious Diseases, 2024

    DOI 10.4084/mjhid.2024.058 PMID 38984092 1 citation (Europe PMC) Open-access full textSource: ORCID

  15. VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

    Clinical Lymphoma, Myeloma and Leukemia, 2024

    DOI 10.1016/j.clml.2024.08.007 PMID 39304364 1 citation (Europe PMC) Source: ORCID

  16. Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

    Blood, 2024

    DOI 10.1182/blood-2024-200071 Source: ORCID

  17. Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

    Leukemia and Lymphoma, 2024

    DOI 10.1080/10428194.2024.2391900 PMID 39141607 2 citations (Europe PMC) Source: ORCID

  18. Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

    Blood, 2024

    DOI 10.1182/blood-2024-205608 37 citations (OpenAlex) Open-access full textSource: OpenAlex

  19. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.7502 26 citations (OpenAlex) Open-access full textSource: OpenAlex

  20. Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

    Blood, 2024

    DOI 10.1182/blood-2024-205077 18 citations (OpenAlex) Source: OpenAlex

  21. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

    Blood, 2024

    DOI 10.1182/blood-2024-200871 14 citations (OpenAlex) Source: OpenAlex

  22. OA-63 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)02344-9 8 citations (OpenAlex) Source: OpenAlex

  23. P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)02315-2 8 citations (OpenAlex) Source: OpenAlex

  24. Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

    Blood, 2024

    DOI 10.1182/blood-2024-199550 4 citations (OpenAlex) Source: OpenAlex

  25. Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

    Blood, 2024

    DOI 10.1182/blood-2024-197908 4 citations (OpenAlex) Source: OpenAlex

  26. P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)02347-4 3 citations (OpenAlex) Source: OpenAlex

  27. OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)01889-5 3 citations (OpenAlex) Source: OpenAlex

  28. OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)01890-1 2 citations (OpenAlex) Source: OpenAlex

  29. Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

    Blood, 2024

    DOI 10.1182/blood-2024-207087 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  30. Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

    Blood, 2024

    DOI 10.1182/blood-2024-201057 2 citations (OpenAlex) Source: OpenAlex

  31. OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8

    Clinical Lymphoma Myeloma & Leukemia, 2024

    DOI 10.1016/s2152-2650(24)01854-8 1 citation (OpenAlex) Source: OpenAlex

  32. PRE-TRANSPLANT DEPRESSION FOUND TO BE RELEATED TO DELAY OF NEUTROPHIL ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS WHO UNDERGO AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION

    2024

    DOI 10.22541/au.172486331.10819573/v1 Open-access full textSource: OpenAlex

  33. Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases

    British Journal of Haematology, 2023

    DOI 10.1111/bjh.19271 PMID 38115798 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  34. A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

    Clinical Lymphoma, Myeloma and Leukemia, 2023

    DOI 10.1016/j.clml.2023.02.007 PMID 36918304 3 citations (Europe PMC) Source: ORCID

  35. A Single Center Real-World Data Comparing Salvage Autologous Hematopoietic StemCell Transplantation, Selinexor Combo and Elranatamab Alone Among Triple Class Refractory Myeloma Patients: Better Efficacy with Elranatamab

    Blood, 2023

    DOI 10.1182/blood-2023-173644 1 citation (OpenAlex) Source: ORCID

  36. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

    Bone Marrow Transplantation, 2023

    Source: ORCID

  37. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

    Bone Marrow Transplantation, 2023

    DOI 10.1007/s12288-022-01524-2 PMID 35747565 Open-access full textSource: ORCID

  38. AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILISATION TECHNIQUES, CELL YIELDS AND PRACTICE VARIATION-BYCOUNTRY IN MYELOMA PATIENTS UNDERGOING FIRST AUTOLOGOUS STEM CELL TRANSPLANTS IN EBMT CENTRES (2012-2021)

    Bone Marrow Transplantation, 2023

    Source: ORCID

  39. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

    Balkan Medical Journal, 2023

    DOI 10.4274/balkanmedj.galenos.2023.2022-2-32 PMID 36959692 1 citation (Europe PMC) Open-access full textSource: ORCID

  40. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

    Blood, 2023

    DOI 10.1182/blood-2023-182741 2 citations (OpenAlex) Open-access full textSource: ORCID

  41. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

    Bone Marrow Transplantation, 2023

    DOI 10.1038/s41409-023-01999-1 PMID 37160942 9 citations (Europe PMC) Open-access full textSource: ORCID

  42. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-LenalidomideDexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

    Blood, 2023

    DOI 10.1182/blood-2023-179416 2 citations (OpenAlex) Source: ORCID

  43. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, 2023

    DOI 10.1038/s41409-023-02048-7 PMID 37543712 3 citations (Europe PMC) Open-access full textSource: ORCID

  44. Comparison of C-11 Methionine and F-18 FDG PET/CT findings in evaluation of Multiple Myeloma: First Turkey Experience

    European Journal of Nuclear Medicine and Molecular Imaging, 2023

    Source: ORCID

  45. Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

    Blood, 2023

    DOI 10.1182/blood-2023-182808 Open-access full textSource: ORCID

  46. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

    Bone Marrow Transplantation, 2023

    Source: ORCID

  47. Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with IntermediateRisk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

    Blood, 2023

    DOI 10.1182/blood-2023-181765 8 citations (OpenAlex) Source: ORCID

  48. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

    Balkan Medical Journal, 2023

    DOI 10.4274/balkanmedj.galenos.2022.2022-2-48 PMID 36571427 10 citations (Europe PMC) Open-access full textSource: ORCID

  49. Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

    Clinical and Experimental Medicine, 2023

    DOI 10.1007/s10238-022-00923-z PMID 36333526 2 citations (Europe PMC) Source: ORCID

  50. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome

    Clinical Lymphoma, Myeloma and Leukemia, 2023

    DOI 10.1016/j.clml.2022.12.007 PMID 36610852 1 citation (Europe PMC) Open-access full textSource: ORCID